Ophthalmology

Editor's Choice

Jeffrey B. Kindler, chief executive officer and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation Catalyst Award.

LATEST ARTICLES

Ophthalmologist's role in preventing diabetic eye disease

Eye-care providers can contribute to early diagnosis, improved prognosis, and prevention of the complications of late-stage eye disease caused by diabetes.

Diabetic retinopathy: Association mapping holds key to understanding mechanism of major diseases

Association mapping is a new perspective on the use of genomic tools that allows study of common disorders, such as diabetic retinopathy, and tries to tease apart genes as a way of studying disease pathophysiology.

PHP device aids CNV detection

A new device for at-home monitoring of age-related macular degeneration is a promising tool for early detection of choroidal neovascularization.

Travoprost: A prostaglandin analogue for the treatment of glaucoma

In August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.

Vasculopathies: Data support intravitreal bevacizumab

Data continue to support intravitreal bevacizumab injection for treatment of radiation maculopathy and radiation optic neuropathy.